Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
Not yet recruiting · NCT07302841 · Registry updated 2025-12-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer Non-resectable | Not yet recruiting | Phase 4 | 2025-12-24 | NCT07302841 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||